Delving into the Latest Updates on Pepscan Therapeutics BV with Synapse

概览

关联

2

项与 Pepscan Therapeutics BV 相关的临床试验

A phase I-II open label clinical trial, evaluating the efficacy and safety of administration of the therapeutic vaccine PEP-223/CoVaccine HT, to hormone treatment naive, immunocompetent subjects with T1-3, N0-1/x, M0 prostate cancer, eligible for hormone therapy. - PEP223-NL-701

开始日期2008-12-10

申办/合作机构

Pepscan Therapeutics BV

NCT00895466 / Unknown status临床1/2期

A Phase I-II Open Label Clinical Trial, Evaluating the Efficacy and Safety of Administration of the Therapeutic Vaccine PEP-223/CoVaccine HT, to Hormone Treatment naïve, Immunocompetent Subjects With T1-3, N0-1/x, M0 Prostate Cancer, Eligible for Hormone Therapy.

The purpose of this trial is to investigate whether treatment with this new drug will result in lower testosterone levels in men with prostate cancer. At the same time it will be investigated whether the drug induces side effects, and if so, which ones.

开始日期2008-10-01

申办/合作机构

Pepscan Therapeutics BV

[+1]

100 项与 Pepscan Therapeutics BV 相关的临床结果

登录后查看更多信息

0 项与 Pepscan Therapeutics BV 相关的专利（医药）

登录后查看更多信息

4

项与 Pepscan Therapeutics BV 相关的文献（医药）

2009-06-18·The Open Vaccine Journal

Functional Reconstruction of Structurally Complex Epitopes using CLIPS™ Technology

作者: Puijk, W. C. ; Slootstra, J. W. ; Huber, A. ; Parren, P. W. H. I. ; Bachmann, M. F. ; Beurskens, F. J. ; Boshuizen, R. S. ; Timmerman, P. ; van Dijken, P. ; Meloen, R. H.

This review summarizes an illustrative set of data from our research on the reconstruction of structurally complex protein surfaces, i.e. those that fail to be mimicked properly by linear peptides.In the past 5 years, our newly developed CLIPS technol. has proven an extremely valuable tool for 1) binding site mapping of therapeutically relevant mAbs, 2) generating hyperimmune sera via immunization with CLIPS peptides, and 3) the generation of monoclonal antibodies (mAbs) via the use of hybridoma technol.We currently have data available for more than 50 therapeutic targets.The examples described in this review illustrate the potential of this powerful new technol.

2008-07-01·The Journal of Biochemistry4区 · 生物学

SUMO Assay with Peptide Arrays on Solid Support: Insights into SUMO Target Sites

4区 · 生物学

Article

作者: van Dijk, Willem J. ; Sixma, Titia K. ; Schwamborn, Klaus ; Meloen, Rob H. ; Langedijk, Johannes P. M. ; Knipscheer, Puck ; van Dijk, Evert

The modification of proteins by SUMO (small ubiquitin-like modifier) regulates various cellular processes. Sumoylation often occurs on a specific lysine residue within the consensus motif psiKxE/D. However, little is known about the specificity and selectivity of SUMO target sites. We describe here a SUMO assay with peptide array on solid support for the simultaneous characterization of hundreds of different SUMO target sites. This approach was used to characterize known SUMO substrates. The position of the motif within the peptide and the amino acids flanking the acceptor site affected the efficiency of SUMO modification. Interestingly, a sequence of only four amino acids, corresponding to the SUMO consensus motif without flanking amino acids, was a bona fide target site. Analysis of a peptide library for all variants of the psiKxE/D consensus motif revealed that the first and third positions in the tetrapeptide preferably contain aromatic amino acid residues. Furthermore, by adding the SUMO E3 ligase PIAS1 to the reaction mixture, we show specific enhancement of the modification of a PIAS1-dependent SUMO substrate in this system. Overall, our results demonstrate that the sumoylation assay with peptide array on solid support can be used for the high-throughput characterization of SUMO target sites, and provide new insights into the composition, selectivity and specificity of SUMO target sites.

Innovations in Pharmaceutical Technology

2-CLIPS bicycle peptides

作者: Timmerman, Peter

A review.In addition to antibody epitope mapping, applications for the CLIPS peptide technol. platform are now being broadened to therapeutic peptide drug discovery, as well as areas such as diagnostics and affinity purification

100 项与 Pepscan Therapeutics BV 相关的药物交易

登录后查看更多信息

100 项与 Pepscan Therapeutics BV 相关的转化医学

登录后查看更多信息